Houston, Texas — (March 4, 2026) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutical company developing potentially life-changing technologies for patients that require stem cell or bone marrow transplantation announced today the appointment of Lisa Bollinger, MD as an advisor to the Company. She will provide strategic leadership relating to FDA strategy …
Houston, Texas — (December 2, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutics company developing potentially life-changing technologies for patients that require stem cell or bone marrow transplantation. The Company announced today the appointment of Vassil Tzenov as Vice President and Chief Financial Officer. Mr. Tzenov will lead and manage the financial requirements of the …
GreenJay Appoints Vassil Tzenov as Vice President and Chief Financial Officer Read More »
Capital Raise Fully Subscribed Houston, Texas — (October 21, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a drug formulation company focused on developing safer, more soluble and more efficacious therapies for patients with leukemia and other blood disorders, announced today that the Company has completed its Series A round of financing. “We are very pleased with …
HOUSTON, Texas — (August 26, 2025) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a late-stage pharmaceutical company focused on developing life-changing therapies for patients requiring stem cell/bone marrow transplants, announced today that the Company has manufactured its registration batches necessary for regulatory approval. Previously, GreenJay completed its preclinical toxicology studies. GreenJay has developed an improved formulation of IV busulfan …
Houston, Texas – (July 30, 2025) – It is with great sadness that we announce the passing of our CEO and beloved friend, James Donald Payne (Donald) on the 13th of May, 2025, after a brave and brief illness at age 69. At Donald’s side for the duration of his illness were his daughters Allison and …
GreenJay Therapeutics Sadly Announces the Passing of Its CEO, Donald Payne Read More »
Houston, Texas — (June 30, 2023) — GreenJay Therapeutics, Inc. (“GreenJay” or the “Company”), a drug formulation company focused on developing safer, more soluble and more efficacious therapies for patients with leukemia and other blood disorders, announced today that the Company has completed its seed round of financing. “We are very pleased with our success …
Allogeneic stem cell transplant is a current treatment option for patients with refractory/relapsed classic Hodgkin’s Lymphoma, including those who have failed an autologous transplantation. Hodgkin’s Lymphoma is one of the most curable forms of cancer. The National Cancer Institute reported the five-year Hodgkin’s Lymphoma survival rate was 69.9% in 1975 and 85.4% in 2009. This increase is due …
– Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT – Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia Go Back to Publications
High-dose chemotherapy with autologous stem cell transplantation has become standard of care for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL). High-dose busulfan, cyclophosphamide and etoposide is an effective regimen resulting in long-term disease-free survival in relapsed malignant lymphoma and prior radiation therapy. The toxicity is moderate with a low treatment-related mortality. NHL patients include diffuse …
Since the early 1990s, chemotherapy followed by an autologous stem cell transplant has been the standard of care for high-risk neuroblastoma, a childhood cancer that starts in nerve cells outside the brain, especially in the tissues of the adrenal glands, and sometimes the neck, chest, or pelvis. Before children receive chemotherapy to destroy the neuroblastoma, …
